论文部分内容阅读
目的探讨美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效。方法选取江苏省苏北人民医院收治的老年重症心力衰竭患者100例,按照随机数字表法分为对照组和观察组,各50例。对照组患者采用常规用药方案治疗,观察组患者在对照组基础上给予美托洛尔联合厄贝沙坦氢氯噻嗪治疗,两组患者均持续治疗6个月。比较两组患者的临床疗效及治疗前后心功能指标[左心室射血分数(LVEF)、B型脑利钠肽(BNP)]变化情况,观察两组患者不良反应发生情况。结果观察组患者治疗总有效率高于对照组(P<0.05)。治疗前,两组患者LVEF、BNP比较,差异无统计学意义(P>0.05);治疗后,观察组患者LVEF高于对照组,BNP低于对照组(P<0.05)。观察组患者不良反应发生率低于对照组(P<0.05)。结论采用美托洛尔联合厄贝沙坦氢氯噻嗪治疗重症心力衰竭的临床疗效确切,可有效改善患者心功能,且安全性好。
Objective To investigate the clinical efficacy of metoprolol combined with irbesartan hydrochloride in elderly patients with severe heart failure. Methods 100 cases of elderly patients with severe heart failure admitted to Jiangsu Provincial People’s Hospital of Jiangsu Province were divided into control group and observation group according to random number table method, 50 cases each. Patients in the control group were treated with conventional drug regimens. Patients in the observation group were treated with metoprolol combined with irbesartan hydrochlorothiazide on the basis of the control group, and both groups were treated for 6 months. The clinical efficacy and the changes of cardiac function index (left ventricular ejection fraction (LVEF) and B-type natriuretic peptide (BNP)] in both groups were compared before and after treatment to observe the adverse reactions of the two groups. Results The total effective rate of observation group was higher than that of control group (P <0.05). Before treatment, there was no significant difference in LVEF and BNP between the two groups (P> 0.05). After treatment, LVEF in observation group was higher than that in control group, BNP was lower than that in control group (P <0.05). The incidence of adverse reactions in observation group was lower than that in control group (P <0.05). Conclusion Metoprolol combined with irbesartan hydrochlorothiazide in the treatment of severe heart failure, the exact clinical efficacy, can effectively improve the patient’s cardiac function, and good safety.